Amgen Discloses FDA Paused Study of Early-Stage Obesity Drug (2)

Amgen Inc.’s disclosed that US regulators paused the study of an early-stage obesity drug, a lucrative market the company is trying to crack.

The Thousand Oaks, California-based drugmaker didn’t say why or when the US Food and Drug Administration placed the trial of AMG-513 on clinical hold, but said in a statement that it was working with the agency to find a path forward.

“We still expect to have that in development,” Chief Executive Officer Robert Bradway told analysts on a conference call.

The company’s shares fell about 1% after markets closed in New York.

Amgen sells drugs in ...